Biomarkers in Acute Kidney Injury.
- Author:
Min Hyun CHO
1
Author Information
1. Department of Pediatrics, Kyungpook National University School of Medicine, Daegu, Korea. chomh@knu.ac.kr
- Publication Type:Review
- Keywords:
Acute kidney injury;
Biomarker;
Children;
NGAL;
KIM-1;
IL-18;
L-FABP
- MeSH:
Acetylglucosaminidase;
Acute Kidney Injury;
Biomarkers;
Child;
Creatinine;
Diagnosis, Differential;
Early Diagnosis;
Humans;
Interleukin-18;
Kidney;
Lipocalins;
Matrix Metalloproteinase 9;
Neutrophils;
Prognosis;
Renal Insufficiency, Chronic
- From:Journal of the Korean Society of Pediatric Nephrology
2011;15(2):116-124
- CountryRepublic of Korea
- Language:Korean
-
Abstract:
Acute kidney injury (AKI) can result in mortality or progress to chronic kidney disease in hospitalized patients. Although serum creatinine has long been used as the best biomarker for diagnosis of AKI, it has some clinical limitations, especially in children. New biomarkers are needed for early diagnosis, differential diagnosis, and reliable prediction of prognosis in AKI. Up to the present, candidate AKI biomarkers include neutrophil gelatinase-associated lipocalin (NGAL), kidney injury molecule-1 (KIM-1), interleukin-18 (IL-18), liver-type fatty acid-binding protein (L-FABP), matrix metalloproteinase-9 (MMP-9), and N-acetyl-beta-D-glucosaminidase (NAG). However, whether these are superior to serum creatinine in the confirmation of diagnosis and prediction of prognosis in AKI is unclear. Further studies are needed for clinical application of these new biomarkers in AKI.
